Table 5. Meta-analysis of rs17879961 (c.470T > C) in CHEK2 and three urinary tract cancers in individual GWAS data.
| Study | OR (95%CI)a | P value | Phetc |
|---|---|---|---|
| Bladder cancer_1M | NAd | NA | |
| Bladder cancer_550 | 0.35 (0.02–7.11) | 0.491 | |
| Bladder cancer_610 | 0.71 (0.52–0.98) | 0.036 | |
| Meta-analysis of three bladder cancers studies | 0.71 (0.51–0.97)b | 0.031 | 0.642 |
| Renal cancer_550 | 0.36 (0.00–91.29) | 0.717 | |
| Renal cancer_610 | 0.50 (0.33–0.77) | 1.5E-03 | |
| Renal cancer_660 | 2.85 (0.06–137.50) | 0.596 | |
| Meta-analysis of three renal cancers studies | 0.51 (0.34–0.78)b | 2.0E-03 | 0.678 |
| Prostate cancer | 1.14 (0.56–2.30) | 0.720 | |
| Meta-analysis of all studies | 0.67 (0.53–0.85)b | 1.0E-03 | 0.438 |
aOR, odds ration; CI, confidence interval. P was for addictive model.
bOR and 95%CI were estimated from a fixed-effects model.
cP value of Cochran’s Q-test for the heterogeneity.
dNA, not available.